Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Subject-blind, Investigator-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of UCB4940 in Subjects With Psoriatic Arthritis

Next Previous
Trial Profile

A Subject-blind, Investigator-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of UCB4940 in Subjects With Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors UCB

    • Most Recent Events

    • 23 Dec 2017 Primary endpoint (Pre-specified efficacy (PoC) endpoint:American College of Rheumatology Index of Improvement (ACRn) at Week 8 (pooled top three doses vs placebo at week 80))has been met, according to results published in the Annals of the Rheumatic Diseases.
    • 23 Dec 2017 Results of the preclinical experiments and a proof of concept (PoC) study assessing the effect of novel dual-cytokine blockade (IL-17A and IL-17F) by Bimekizumab versus placebo, published in the Annals of the Rheumatic Diseases.
    • 10 Jun 2016 According to an UCB media release, positive results (n=52) were presented at the Annual European Congress of Rheumatology (EULAR) 2016.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top